Investor Relations Home

About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%)0.00 (0.00%)
Data as of 12/10/18 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $17.12 with a 52 week high of $29.62 and a 52 week low of $8.60.

Recent News

Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response - 12/06/18
Study Demonstrates Utility of Assay in Neoadjuvant and Adjuvant Treatment Settings SAN CARLOS, Calif., Dec. 6, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presente... More»
Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study - 11/29/18
Primary study results on the 20,000 patients anticipated in 2019 to validate the clinical utility of routine screening for microdeletion genetic conditions SAN CARLOS, Calif., Nov. 29, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global l... More»
Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test - 11/28/18
Represents a Key Milestone Towards Achieving Medicare Reimbursement SAN CARLOS, Calif., Nov. 28, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for th... More»
Natera Reports Third Quarter 2018 Financial Results - 11/08/18
SAN CARLOS, Calif., Nov. 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2018, and... More»
Natera Announces Third Quarter 2018 Earnings Conference Call - 11/01/18
SAN CARLOS, Calif., Nov. 1, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended Sept. 30, 2... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.